{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:03:00Z","timestamp":1778828580778,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.eimc.2014.09.005","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T09:33:29Z","timestamp":1415093609000},"page":"298-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital"],"prefix":"10.1016","volume":"33","author":[{"given":"Evelyn","family":"Cabral-Galeano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Ruiz-Camps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Len-Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Pou-Clav\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Sord\u00e9-Masip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Meije-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Blanco-Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Barba-Su\u00f1ol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Monforte-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rom\u00e1n-Broto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Pahissa-Berga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Gavald\u00e0-Santapau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2014.09.005_bib0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.eimc.2014.09.005_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.09.005_bib0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.09.005_bib0020","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.09.005_bib0025","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.09.005_bib0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.00957-06","article-title":"Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods","volume":"51","author":"Pascual","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.09.005_bib0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome p450 2c19 genetic status","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.09.005_bib0040","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome p450 2c19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.09.005_bib0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/00912700222011445","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.09.005_bib0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.09.005_bib0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.09.005_bib0060","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eimc.2014.09.005_bib0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2014.09.005_bib0070","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.09.005_bib0075","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1345\/aph.1L243","article-title":"Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis","volume":"42","author":"Howard","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"Suppl. 2","key":"10.1016\/j.eimc.2014.09.005_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2012.03772.x","article-title":"Antifungal prophylaxis in haematology patients: the role of voriconazole","volume":"18","author":"Hicheri","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 4","key":"10.1016\/j.eimc.2014.09.005_bib0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ajt.12115","article-title":"Aspergillosis in solid organ transplantation","volume":"13","author":"Singh","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2014.09.005_bib0090","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.09.005_bib0095","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.09.005_bib0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.09.005_bib0105","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.05219-11","article-title":"A prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels and associations between serum troughs, efficacy and toxicity","volume":"56","author":"Mitsani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.09.005_bib0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1399-3062.2009.00384.x","article-title":"Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients","volume":"11","author":"Berge","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimc.2014.09.005_bib0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/13693786.2011.630039","article-title":"Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients","volume":"50","author":"G\u00f3mez-L\u00f3pez","year":"2012","journal-title":"Med Mycol"},{"key":"10.1016\/j.eimc.2014.09.005_bib0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","article-title":"Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance","volume":"13","author":"de Groot","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.09.005_bib0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2710.2009.01061.x","article-title":"Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis","volume":"35","author":"Thomas","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.eimc.2014.09.005_bib0130","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.09.005_bib0135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis in adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.09.005_bib0140","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/RHU.0b013e318188bea7","article-title":"Voriconazole-associated myositis","volume":"15","author":"Shanmugam","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.eimc.2014.09.005_bib0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0773.1999.tb01059.x","article-title":"Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers","volume":"85","author":"Varis","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.eimc.2014.09.005_bib0150","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14003176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14003176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T01:54:12Z","timestamp":1538099652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X14003176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0213005X14003176"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2014.09.005","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2014.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}